The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology

The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology

Guidelines for genetic testing have been established for multiple tumor types, frequently indicating the most confident molecularly targeted treatment options. However, considering the often-complex presentation of individual cancer patients, in addition to the combinatorial complexity and inherent...

Full description

Bibliographic Details
Main Authors: Sigve Nakken, Wolfgang Lilleby, Marta D. Switlyk, Karen E. Knudsen, Oscar Lilleby, Sen Zhao, Fatemeh Kaveh, Per O. Ekstrøm, Alfonso Urbanucci, Eivind Hovig
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Personalized Medicine
Subjects:
prostate cancer
disease management
genomic testing
guidelines
treatment biomarkers
Online Access:https://www.mdpi.com/2075-4426/11/5/330

Internet

https://www.mdpi.com/2075-4426/11/5/330

Similar Items